abstract: Fetal ovarian development and primordial follicle formation are imperative for adult fertility in the female. Data suggest the interleukin (IL)6-type cytokines, leukaemia inhibitory factor (LIF), IL6, oncostatin M (OSM) and ciliary neurotrophic factor (CNTF), are able to regulate the survival, proliferation and differentiation of fetal murine germ cells (GCs) in vivo and in vitro. We postulated that these factors may play a similar role during early human GC development and primordial follicle formation. To test this hypothesis, we have investigated the expression and regulation of IL6-type cytokines, using quantitative reverse transcription polymerase chain reaction and immunohistochemistry. Expression of transcripts encoding OSM increased significantly across the gestational range examined (8 -20 weeks), while expression of IL6 increased specifically between the first (8-11 weeks) and early second (12 -16 weeks) trimesters, co-incident with the initiation of meiosis. LIF and CNTF expression remained unchanged. Expression of the genes encoding the LIF and IL6 receptors, and their common signalling subunit gp130, was also found to be developmentally regulated, with expression increasing significantly with increasing gestation. LIF receptor and gp130 proteins localized exclusively to GCs, including oocytes in primordial follicles, indicating this cell type to be the sole target of IL6-type cytokine signalling in the human fetal ovary. These data establish that IL6-type cytokines and their receptors are expressed in the human fetal ovary and may directly influence GC development at multiple stages of maturation.
Introduction
Ovarian development is a complex process composed of several highly regulated stages, which determine a female's future fertility (Maheshwari and Fowler, 2008; Tingen et al., 2009) . In mammals, primordial germ cells (PGCs) form in the proximal epiblast and migrate to and populate the genital ridges (Lawson and Hage, 1994) . During migration, the GCs begin to proliferate and continue to do so upon arrival to the gonad. Following sex determination, the GCs in the nascent ovary initially continue to proliferate, but undergo incomplete cell division to form syncytial GC nests or clusters, which progressively enter meiosis from 11-week gestation onwards in the human (Gondos et al., 1986; Hibi et al., 1990) . The subsequent breakdown of GC nests, during which the majority of oocytes are lost (Pepling and Spradling, 2001) , allows the remaining oocytes to associate with somatic cells to form primordial follicles, a process which commences around 18-week gestation (Maheshwari and Fowler, 2008) and is completed by birth in humans. The process of GC development from PGCs to oocytes in primordial follicle is extensively regulated by extrinsic growth factor signals, including KIT ligand (KL), Wnt proteins and members of the transforming growth factor-b superfamily (Taga and Kishimoto, 1992) ; however, the complete pathway by which GCs develop from PGCs to oocytes in primordial follicles is poorly understood. Elucidating these signalling pathways is important, as disruption of primordial follicle formation may result in premature ovarian insufficiency or infertility in adulthood (Laissue et al., 2008) .
The interleukin (IL)6-type cytokines, which include IL6, leukaemia inhibitory factor (LIF), oncostatin M (OSM), and ciliary neurotrophic factor (CNTF), are well-characterized regulators of the immune response. IL6-type cytokines also play key roles in the regulation of cell proliferation, differentiation and survival during embryonic development (Heinrich et al., 1998) . LIF has a well-characterized role in the maintenance of pluripotency in mouse embryonic stem (ES) cells (Williams et al., 1988) and, consistent with this, can [in the presence of basic fibroblast growth factor (bFGF) and KL] promote the conversion of PGCs into pluripotent ES cell-like embryonic germ (EG) cells (Matsui et al., 1991; Resnick et al., 1992) . LIF can also increase isolated mouse PGC numbers in vitro (Defelici and Dolci, 1991; Cheng et al., 1994) , as does OSM, CNTF or IL-6 (when cultured in the presence of the soluble isoform of its receptor) (Resnick et al., 1992; Cheng et al., 1994; Koshimizu et al., 1996) . It has been suggested that this results from an anti-apoptotic action of IL6-type cytokines on GCs, rather than through the promotion of proliferation (Pesce et al., 1993) . LIF (and IL-6 in conjunction with soluble receptor) also inhibits the spontaneous entry of mouse primordial GCs into meiosis (Chuma and Nakatsuji, 2001 ) and has been shown to promote the primordial to primary follicle transition in vitro .
The IL6-type cytokines signal by forming dimers or trimers of various receptor components including two shared components glycoprotein-130 (gp130) and LIF receptor (LIFR; reviewed in Heinrich et al., 1998) . LIF and OSM signal via heterodimeric complexes of gp130 in combination with LIFR, and additionally, OSM can signal through an alternative receptor complex consisting of gp130 and an OSM specific receptor (OSMR). CNTF utilizes a specific heterotrimeric complex of gp130, LIFR and a specific a-receptor subunit CNTF receptor (CNTFR). IL6 also signals via a trimeric complex consisting of a gp130 homodimer combined with its specific a-receptor subunit IL6 receptor (IL6R). The a-receptor subunits (IL6R and CNTFR), although necessary for the formation of specific receptor complexes, do not themselves transduce signal, whereas gp130, LIFR and OSMR trigger phosporylation of Janus (JAK) kinases, in order to activate the Jak/STAT signalling cascade (Heinrich et al., 1998) . As a direct result of utilizing similar receptor complexes, the IL6-type cytokines have overlapping biological activity (Taga and Kishimoto, 1997) , and this biological redundancy has hindered efforts to elucidate the function of specific ligands. Thus, in vivo results from genetically engineered animal models with target disruptions of IL6-type ligands and receptors have not recapitulated the effects of IL6-type cytokines on GCs in vitro (Stewart et al., 1992; Escary et al., 1993; Ware et al., 1995; Yoshida et al., 1996; Molyneaux et al., 2003) .
Transcripts encoding LIF, gp130 and LIFR are expressed in the late fetal and adult human, and receptors are localized to oocytes (Abir et al., 2004) . However, the expression of these factors during the key developmental window encompassing PGC proliferation, the initiation of meiosis and the formation of primordial follicles in the human fetal ovary has not been previously reported. We therefore examined the expression of LIF, IL6, OSM and CNTF, as well as their receptor components in the human fetal ovary across increasing gestation from 8 to 20 weeks. We also investigated the expression and localization of gp130 and LIFR proteins to determine the cellular target(s) of IL6-type signalling, as a basis for understanding the roles that these cytokines might play in vivo in the human.
Materials and Methods

Tissue collection and dissection
Human fetuses (8-20 weeks) were obtained following medical or surgical termination of pregnancy. Informed consent was given and the study approved by the Lothian Research Ethics Committee (LRC08/S1101/1). All specimens were morphologically normal. Gonads were dissected into Dulbecco's phosphate-buffered saline (Invitrogen, Paisley, UK) and mesonephric tissue removed. Sex of first trimester specimens was determined by SRY PCR genotyping (Davis et al., 1993) . Ovaries were snap frozen at 2808C prior to RNA extraction or fixed in Bouin's solution for immunohistochemistry.
RNA extraction and cDNA synthesis
Total RNA was extracted using RNeasy Micro Kit (Qiagen Ltd, Crawley, UK) with on-column DNaseI digestion as per the manufacturer's instructions. First-strand cDNA synthesis was performed using Superscript VILO Master Mix (Invitrogen) according to the manufacturer's instructions. Duplicate negative control reactions in which the reverse transcriptase enzyme was omitted were also performed.
Quantitative real-time PCR
Quantification of mRNA expression relative to the housekeeping gene GAPDH was performed using PowerSYBR Green Master Mix and the ABI7500Fast system (both Applied Biosystems, Warrington, UK) under standard running conditions. Output was assessed and analysed as described previously (Bayne et al., 2009 ) using the 2 −DDCt method of quantification.
Primer sequences utilized for this study are detailed in Table I .
Immunohistochemistry
Ovarian sections (5 mm) were mounted on electrostatically charged microscope slides (VWR, Chicago, IL, USA), dewaxed and rehydrated. Immunohistochemistry was performed as described previously (Childs et al., 2010b) 
IL6-type cytokines in human fetal ovary by western blotting (gp130: Rebouissou et al., 2009 , LIFR: Wysoczynski et al., 2007 . Bound primary antibody was detected using a goat anti-rabbit biotinylated secondary antibody (1:500, Vector, Burlingame, CA, USA). Negative controls in which the primary antibody was omitted were performed in parallel. Images were captured using an Olympus Provis microscope (Olympus, London, UK).
Statistical analysis
Quantitative reverse transcription polymerase chain reaction (qRT-PCR) data were analysed by ANOVA with either the Newman-Keuls or linear trend post hoc tests using GraphPad Prism 5.0 software (GraphPad Software, CA, USA).
Results
Genes encoding IL6 ligands display distinct developmentally regulated expression patterns during human fetal ovarian development
To determine the presence and pattern of expression of transcripts encoding IL6-type cytokines during human fetal ovarian development, we performed qRT-PCR for IL6, LIF, OSM and CNTF across a range of gestations. Ovarian specimens were grouped into three gestational stages to broadly reflect the key developmental events of early to mid-gestation ovarian development, namely the proliferation of undifferentiated PGCs (8-11 weeks gestation; first trimester), the formation of GC nests and entry of the first GCs into meiosis (13-16 weeks; early second trimester) and ongoing meiotic entry and the onset of primordial follicle formation (17 -20 weeks; late second trimester). Transcripts encoding all four ligands investigated were detected in the human fetal ovary. Expression of transcripts encoding IL6 increased by a modest but significant amount between 8-11 and 13-16 (1.6 + 0.3 × 10 24 versus 3.0 + 0.4 × 10 24 relative to expression of the housekeeping gene GAPDH, P ¼ 0.03, n ¼ 5-6 per group) weeks of gestation, but declined subsequently, such that expression at 17 -20 weeks (1.9 + 0.2 × 10 24 relative to GAPDH)
was significantly lower than that at 13-16 weeks [but not significantly different from 8 to 11 weeks (P ¼ 0.04; Fig. 1A) ]. OSM expression increased significantly with increasing gestation, starting at a borderline detectable level at 8-11 weeks (2.3 + 0.5 × 10 25 relative to GAPDH), increasing at 13 -16 weeks (9.2 + 3.1 × 10 25 relative to GAPDH) and again at 17 -20 weeks (1.9 + 0.8 × 10 24 relative to GAPDH, linear trend P ¼ 0.04; Fig. 1B ). In contrast, the expression of LIF and CNTF did not change significantly across the gestational range examined (P ¼ 0.69 and 0.17 respectively; Fig. 1C and D) . Transcript levels for CNTF were variable. These data reveal that transcripts encoding IL6 and OSM are developmentally regulated but expression of LIF and CNTF is not.
Expression of transcripts encoding LIFR, OSMR and gp130 are developmentally regulated during human fetal ovarian development
We next examined the expression of transcripts encoding the IL6-type cytokine receptors gp130, LIFR, OSMR and IL6R across the gestational range outlined above (n ¼ 5 -6 per gestational group). Expression of transcripts encoding both the common signalling receptor components (gp130 and LIFR) increased between the first and second trimesters. The mRNA expression of gp130 was significantly greater at 13 -16 weeks (2.1 + 0.3 × 10 22 relative to GAPDH, P ¼ 0.02) and 17 -20 weeks (2.1 + 0.3 × 10 22 relative to GAPDH, P ¼ 0.05; Fig. 2A ) than at 8-11 weeks (1.0 + 0.1 × 10 22 relative to GAPDH).
The mRNA expression of LIFR displayed a similar pattern, with expression at 8-11 weeks (1.3 + 0.2 × 10 22 relative to GAPDH) significantly lower than that at both 13-16 weeks (5.9 + 1.2 × 10 22 relative to GAPDH, P ¼ 0.01) and 17-20 weeks (7.4 + 1.6 × 10 22 relative to GAPDH, P ¼ 0.01; Fig. 2B ). IL6R, which is required for the IL6 signalling complex, but does not actively signal itself, was higher at 17 -20 weeks (8.8 + 0.9 × 10 22 relative to GAPDH) compared with both 8-11 weeks (3.5 + 0.6 × 10 22 relative to GAPDH, P ¼ 0.002) and 13-16 weeks (1.8 + 0.7 × 10 22 relative to GAPDH, P ¼ 0.0003; Fig. 2C ). Expression of OSMR, which also conducts intracellular signalling, displayed a similar trend to that of transcripts encoding gp130 and LIFR (i.e. increasing with gestation) but showed no significant changes across the gestational range examined (Fig. 2D ). These data demonstrate that the two common receptor components and the IL6-specific component increase with gestation.
gp130 and LIFR are expressed exclusively by the GCs in the human fetal ovary
To determine the cellular target(s) of IL6-type cytokine signalling in the human fetal ovary, we performed immunohistochemistry to detect the functional receptor components gp130 and LIFR across the developmental window outlined above. At 8-week gestation, gp130 expression was detected in GCs, but staining was weak and sporadic and many GCs displayed no staining (Fig. 3A) . In contrast, from IL6-type cytokines in human fetal ovary 14-week gestation, expression was stronger and restricted to GCs, with stromal cell streams and pre-granulosa cells not showing any expression ( Fig. 3B and C) , a pattern maintained in later gestations ( Fig. 3D and E) . Staining was also detected in oocytes in primordial follicles at 20-week gestation (Fig. 3E, inset) , revealing that GCs continue to express gp130 following nest breakdown and follicle assembly. The expression pattern of LIFR in the human fetal ovary was similar to that of gp130, with staining detected exclusively in GCs from 8 weeks of gestation onwards (Fig. 4A-D) . Notably, GCs displayed variability in the intensity of LIFR staining even within close proximity (Fig. 4E) . At 20-week gestation, oocytes within primordial follicles expressed LIFR (Fig. 4E, inset) . The expression pattern of the two shared, functional signalling components indicates that IL6-type cytokines are able to signal to GCs in the fetal ovary; indeed, GCs appear the sole cell type involved.
Discussion
GC development and primordial follicle formation are vital to female fertility. Extensive in vitro studies have demonstrated roles for LIF and other IL6-type cytokines in the regulation of GC development (Matsui et al., 1991; Resnick et al., 1992; Cheng et al., 1994; Koshimizu et al., 1996; Chuma and Nakatsuji, 2001; Nilsson et al., 2001) . However, little evidence has been provided regarding their potential roles during human fetal ovarian development. The data presented here confirm that all IL6-type cytokines previously demonstrated to regulate murine GC development in vitro (LIF, IL6, OSM and CNTF) are expressed in the human fetal ovary, as are their common receptor components. Furthermore, the expression of the latter is confined to GCs, revealing these cells to be the exclusive targets of IL6-type signalling in the human fetal ovary.
Expression of the genes encoding IL6-type signalling components was found to be developmentally regulated, a finding consistent with the immunohistochemistry data also presented here. Unexpectedly, the finding that gp130 expression is low or undetectable in primordial GCs in the first trimester human fetal ovary suggests that these cells have little or no capacity to receive and/or transduce IL6-type cytokine signals, and implies that, as in rodents (Molyneaux et al., 2003) , gp130 signalling activity is not required for the survival of human PGCs or their maintenance in an undifferentiated state in vivo. The mRNA and protein levels of both gp130 and LIFR appear to be up-regulated in the early second trimester, however. This coincides with the entry of the first GCs into meiosis (Gondos et al., 1986; Hibi et al., 1990) and indicates that IL6-type signalling may be important in the regulation of this critical event. As both LIF and IL6 are reported to inhibit the spontaneous initiation of meiosis of isolated mouse PGCs in culture (Chuma and Nakatsuji, 2001) , it is possible that up-regulation of receptor expression functions to prevent precocious entry into meiosis, maintaining an immature cell population that can still undergo further proliferation. The absence of signalling in first-trimester GCs, and the lack of an apparent restriction of gp130 and LIFR expression to undifferentiated, pre-meiotic GCs found at the periphery of the secondtrimester human fetal ovary (Anderson et al., 2007) , casts doubt on this hypothesis. More likely, IL6-type cytokines play a role in promoting the survival of differentiating/meiotic GCs. Consistent with this, a modest anti-apoptotic effect was reported when LIF treatment was applied to GCs in 3-day cultures of fetal mouse ovaries isolated from e13.5 mice [a development stage comparable to that of the early second-trimester (13 -16 weeks of gestation) specimens reported here] (Morita et al., 1999) . Of particular note is the striking variability in expression of LIFR in between GCs, particularly at later gestations, similar to that we have reported recently for brain-derived neurotrophic factor (BDNF) (Childs et al., 2010a) . Given the anti-apoptotic role of IL6-type cytokines for GCs at this developmental stage (Morita et al., 1999) , it is possible that the GCs expressing the highest level of LIFR may gain a selective survival advantage during the wave of oocyte death that accompanies nest breakdown and follicle formation. The increased expression of IL6R specifically in the late second trimester (as nest breakdown and primordial follicle formation commence) is also consistent with this hypothesis.
Expression patterns of the IL6-type ligand transcripts are more varied. OSM expression increased linearly with development, while no change was detected in the expression of LIF, which is postulated to be involved in ovarian development Nilsson et al., 2002) , or CNTF across the gestational range examined (although the high variability in CNTF expression between specimens may mask such a change). Each of these ligands utilizes the same LIFR/gp130 receptor complex; however, only OSM displays increasing expression with gestation similar to that of the two receptor components. The expression of both IL6 and its specific receptor IL6R is also increased in the second IL6-type cytokines in human fetal ovary trimester, albeit at slightly different developmental stages. Together, these data demonstrate that multiple components of the IL6-type cytokine signalling machinery are up-regulated in the second-trimester human fetal ovary, suggesting potential roles for these factors in the later stages of GC development and primordial follicle formation.
Signalling by IL6-type cytokines has been reported to interact with other key signalling pathways that regulate mammalian ovarian development. OSM up-regulates the growth factor bFGF in vitro (Wijelath et al., 1997) , which promotes primordial follicle formation (Nilsson et al., 2001) . Similarly, KL expression is regulated by LIF in rodent ovarian culture and is able to activate differentiation and promote survival in GCs . It has thus been proposed that bFGF, KL and the IL6-type cytokines have similar functions and work synergistically in vivo in the ovary . In addition to interactions with bFGF and KL, the IL6-type cytokines have been shown to interact in non-reproductive organs with cytokines known to regulate human ovarian development. LIF and BMP2, signalling through STAT3 and SMAD1, respectively, are known to act synergistically in promoting the differentiation of astrocytes from cultures of fetal neuronal precursor cells (Nakashima et al., 1999) . We have recently reported increased expression of BMP2 and SMAD1 in the second-trimester human fetal ovary and identified GCs to be the exclusive targets of BMP signalling in this tissue (Childs et al., 2010b) ; thus, the apparatus for such a synergistic interaction between IL6-type cytokine and BMP signalling also exists in human fetal ovarian GCs. LIF also acts synergistically with the neurotrophin BDNF to promote cell survival and proliferation in the developing rodent brain (Marzella et al., 1999) . This is similar to the known role for BDNF in the rodent ovary (Spears et al., 2003; Paredes et al., 2004; Childs et al., 2010a) .
To date, animal models have failed to determine in vivo roles for the IL6-type cytokines during ovarian development. Female Lif 2/2 mice do manifest an infertility phenotype, but as a result of an implantation defect, rather than a disruption of GC development (Stewart et al., 1992; Escary et al., 1993) . Successful ovulation of viable oocytes was confirmed, but quantity of follicles and long-term fertility were not examined. Interestingly, LIF-deficient mice display a significant loss of stem cell populations in the spleen and bone marrow (Escary et al., 1993) . To bypass the difficulty of IL6 ligand redundancy, mouse models with targeted disruptions of the genes encoding the gp130 and LIFR receptors have been generated, however, both models result in either embryonic or early post-natal lethality (Ware et al., 1995; Yoshida et al., 1996) , precluding a detailed analysis of their fertility. A mouse model in which gp130 is conditionally disrupted only in GCs (gp130 △/△ ) has also been generated (Molyneaux et al., 2003) .
Embryonic day (e) 13.5 gp130 △/△ males showed significantly fewer PGCs, but mature males were fertile. Embryonic females had no difference in GC number; adult homozygous recessive females were infertile or produced small litters due to defects in ovulation or late oocyte maturation. gp130 △/△ females also had fewer primary follicles, but no difference in the number of primordial follicles. Although this study does not explore the possible functions of the IL6-type cytokines, it does confirm that they signal solely to the GCs in the human fetal ovary at the gestations examined. Both the shared signalling components gp130 and LIFR, one or both of which are necessary for the formation of all IL6-type signalling complexes, were immunohistochemically localized in GCs and primordial follicles, suggesting any role the IL6-type cytokines would be via direct regulation of the GCs. Previous reports regarding LIF localization in the human ovary suggest that this is via juxtacrine signalling from pre-granulosa stromal cells or autocrine signalling from the GCs themselves (Abir et al., 2004) .
In conclusion, these data demonstrate that IL6-type cytokines are expressed in the human fetal ovary during GC development and that GCs are the sole target of IL6-type action in the fetal ovary. Additionally, transcripts for both ligands and receptors are developmentally regulated, increasing with gestation, suggesting that the IL6-type cytokines are important for in vivo development of the human ovary, predominantly regulating the transition of differentiating GCs from the formation of GC nests, through the entry into meiosis and the formation of primordial follicles.
